Test Price
2,800 AED✅ Home Collection Available
SCN1A Gene Sequencing for GEFS+ Type 2 – Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
✓ Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by a Consultant Medical Geneticist.
✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Targeted NGS sequencing of SCN1A detects pathogenic variants underlying Generalized Epilepsy with Febrile Seizures Plus (GEFS+) Type 2, enabling precise diagnosis, tailored antiepileptic therapy, and informed family planning.
Test Overview & Methodology
The SCN1A Gene NGS test detects pathogenic variants associated with Generalized Epilepsy with Febrile Seizures Plus (GEFS+) Type 2, a channelopathy linked to sodium channel dysfunction. This targeted sequencing approach provides high-depth coverage of all coding exons and flanking intronic regions of SCN1A, ensuring 99.9% diagnostic sensitivity for variant detection.
| Feature | Our SCN1A NGS Test | Closest Alternative (Whole Exome Sequencing) |
|---|---|---|
| Precision | 99.9% sensitivity for SCN1A variants; targeted deep sequencing | Broad coverage but lower depth; incidental findings common |
| Methodology | NGS (Next Generation Sequencing) targeted panel | Exome-wide NGS |
| Turnaround Time | 3–4 Weeks | 8–12 Weeks |
Physician Insight & Safety Protocols
“As a Consultant Medical Geneticist, I recognize the complexity that accompanies genetic testing for epilepsy. The SCN1A variant can clarify seizure etiology and guide antiepileptic drug selection, yet a negative result does not exclude other genetic epilepsies. All findings should be discussed with the treating neurologist to develop a personalized management strategy.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA: 9294403)
Important Clinical Advisory
⚠️ Medication Safety Notice:
Do not discontinue or alter prescribed antiepileptic medication without consulting your doctor. Abrupt changes can provoke severe seizures or status epilepticus.
Exclusion Criteria & Safety Red Flags
- Not suitable for acute emergency diagnosis; requires stable clinical setting.
- Not a substitute for continuous neurological evaluation.
- Potential incidental findings will be discussed during post-test counselling by a genetic specialist.
- If you experience new or worsening seizures, status epilepticus, or severe adverse drug reactions, seek immediate emergency medical attention.
Patient FAQ & Clinical Guidance
1. What is the clinical utility of the SCN1A gene test?
This test identifies pathogenic variants in the SCN1A gene linked to GEFS+ Type 2, enabling precise diagnosis, tailored antiepileptic therapy, and informed family planning. It differentiates SCN1A-associated epilepsy from other febrile seizure syndromes, guiding neurologists in avoiding sodium channel blocking drugs that may aggravate seizures.
2. How is the sample collected and what is the turnaround time?
A venous blood sample is collected by DHA-licensed phlebotomists using temperature-controlled cold-chain logistics, then sequenced using NGS with a 3–4 week reporting time. VIP Mobile Phlebotomy home collection is available daily from 8 AM to 11 PM across the UAE; samples are transported at 2–8°C directly to our ISO-certified genetics laboratory.
3. What should I do after receiving a positive result?
Consult a neurologist and a clinical geneticist immediately for interpretation, family screening, and individualized management; never adjust antiepileptic drugs without professional supervision. A positive SCN1A variant may prompt cascade testing in at-risk relatives and influence medication choices.
UAE Regulatory & Data Privacy Adherence
This test and associated data handling comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. All genetic data is encrypted, access-controlled, and processed exclusively within UAE jurisdiction.
Clinical & Logistical Metadata
| Test Name | SCN1A Gene Sequencing for GEFS+ Type 2 (NGS Targeted Panel) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) or FTA Card |
| Methodology Used | Next Generation Sequencing (NGS) – Targeted Gene Panel |
| ICD-10-CM Code | G40.3 (Generalized idiopathic epilepsy and epileptic syndromes) |
| LOINC Code | 48306-0 (SCN1A gene mutation analysis) |
| DHA Facility License & Laboratory Address | License No: 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians